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aBstRact  Among 2,186 U.S. adults with invasive cancer and laboratory-confi rmed SARS-
CoV-2 infection, we examined the association of COVID-19 treatments with 30-day 
all-cause mortality and factors associated with treatment. Logistic regression with multiple adjust-
ments (e.g., comorbidities, cancer status, baseline COVID-19 severity) was performed. Hydroxychloro-
quine with any other drug was associated with increased mortality versus treatment with any COVID-19 
treatment other than hydroxychloroquine or untreated controls; this association was not present with 
hydroxychloroquine alone. Remdesivir had numerically reduced mortality versus untreated controls 
that did not reach statistical signifi cance. Baseline COVID-19 severity was strongly associated with 
receipt of any treatment. Black patients were approximately half as likely to receive remdesivir as 
white patients. Although observational studies can be limited by potential unmeasured confound-
ing, our fi ndings add to the emerging understanding of patterns of care for patients with cancer and 
COVID-19 and support evaluation of emerging treatments through inclusive prospective controlled 
trials. 
 SIGnIfICAnCE:  Evaluating the potential role of COVID-19 treatments in patients with cancer in a 
large observational study, there was no statistically signifi cant 30-day all-cause mortality benefi t with 
hydroxychloroquine or high-dose corticosteroids alone or in combination; remdesivir showed potential 
benefi t. Treatment receipt refl ects clinical decision-making and suggests disparities in medication 
access. 
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 intRoduction 
 With the onset of the World Health Organization (WHO)–
designated global COVID-19 pandemic, a crucial need 
emerged to discover or repurpose safe and effective treat-
ments to mitigate the severity and mortality of the disease. 
This need is particularly apparent for patients with cancer, 
in whom COVID-19 can have serious consequences. In a 
very large observational study, patients with cancer appear 
to be at increased risk of COVID-19 mortality, independent 
of any specifi c treatment received for COVID-19 ( 1 ). The 
initial study of COVID-19 and Cancer Consortium (CCC19) 
data found that 30-day all-cause mortality was 13% among 
patients with active or prior cancer and confi rmed SARS-
CoV-2 infection ( 2 ). This analysis suggested increased 30-day 
all-cause mortality among patients receiving the combina-
tion of hydroxychloroquine plus azithromycin. Other factors 
associated with increased mortality included age, male sex, 
former smoking status, number of comorbidities, Eastern 
Cooperative Oncology Group performance status (ECOG PS) 
of 2 or higher, and active cancer. 
 Currently, there is not yet peer-reviewed published evi-
dence from randomized clinical trials (RCT) evaluating new 
potential therapies or preventive strategies that demonstrate 
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a significant improvement in mortality outcomes in patients 
with COVID-19 and cancer. Given the historical challenges 
of clinical trial accrual, in particular for patients with cancer, 
the pace of the pandemic is outpacing the rate of prospec-
tive evidence generation, making observational data of great 
importance. In a large promising randomized study evaluat-
ing multiple treatment options, the UK RECOVERY trial, 
cancer is not included as a specific measured comorbidity in 
preliminary reports (3).
Our previous study examined risk factors associated with 
30-day all-cause mortality, including the receipt of hydroxy-
chloroquine alone or in combination with azithromycin, 
although only partial adjustment was possible due to limited 
numbers of events. This association could be influenced by 
confounding factors, that is, patient or clinical character-
istics that could be associated with both COVID-19 treat-
ment receipt and mortality. This follow-up study aims to 
identify factors associated with the receipt of COVID-19 
treatments and to analyze their potential impact on 30-day 
all-cause mortality among patients with active or prior can-
cer and SARS-CoV-2 infection after a robust adjustment 
for additional baseline factors. Our hypotheses were that 
hydroxychloroquine (primary hypothesis) and other plausible 
anti–COVID-19 medications, namely remdesivir, tocili-
zumab, and high-dose corticosteroids (secondary hypothe-
ses), are correlated with mortality in patients with cancer who 
are diagnosed with COVID-19 after adjustment for potential 
confounding. We also conducted a secondary analysis of 
patient factors associated with receipt of any anti–COVID-19 
treatment, the combination of hydroxychloroquine plus 
azithromycin, and remdesivir.
Results
The study cohort included 2,186 patients meeting the 
study inclusion criteria for evaluation of treatment patterns 
and outcomes who accrued between March 17 and June 26, 
2020 (Fig. 1). Overall cohort demographic and clinical patient 
characteristics are shown in Fig. 2 and Supplementary Table 
S1, along with the characteristics of each treatment exposure 
group. Baseline COVID-19 severity was mild in 1,037 (47%), 
moderate in 876 (40%), and severe in 273 (12%). Patients 
received the following treatments, alone or in combination, 
in decreasing prevalence: hydroxychloroquine (n = 538, 25%), 
azithromycin (n = 485, 22%), remdesivir (n = 124, 6%), high-
dose corticosteroids (n = 109, 5%), tocilizumab (n = 94, 4%), 
and other therapy (n = 90, 4%); no treatment was reported for 
1,321 (60%) patients.
The median age of included patients was 67 years [inter-
quartile range (IQR), 57–77], 1,078 (49%) were male, 1,115 
(51%) were non-Hispanic white, and 1,011 (46%) were resi-
dents of the northeast United States. There were 1,115 
(51%) patients in remission from cancer, 607 (28%) had 
present cancer that was stable or responding to treatment, 
and 239 (11%) had actively progressing cancer. Of those in 
remission, 149 (13%) were receiving active antineoplastic 
treatment. Conversely, 116 (49%) patients with progressing 
cancer had not received antineoplastic treatment within 
four weeks of COVID-19 diagnosis; 50 (43%) of these 
patients received some form of COVID-19 treatment. There 
were 749 (34%) patients with an ECOG PS of 0, 563 (26%) 
with ECOG PS of 1, and 352 (16%) with ECOG PS of 2 
or greater. The majority of patients presented with solid 
tumors (n = 1,781, 81%), of which breast cancer was the 
most common (n = 455, 21%). Comorbidity prevalence was 
examined for the following conditions within the cohort: 
obesity (n = 705, 32%), diabetes mellitus (n = 643, 29%), 
hypertension (n = 1,258, 58%), pulmonary conditions (n = 
471, 22%), cardiovascular conditions (n = 709, 32%), and 
renal conditions (n = 389, 18%). Patients received a variety 
of concomitant medications including aspirin or other 
antiplatelet agents (n = 682, 31%), anticoagulants (n = 1087, 
50%), statins (n = 927, 42%), and low-dose corticosteroids (n = 
184, 8%). The percentage of patients receiving anticoagula-
tion in the treatment groups was higher, ranging from 73% 
to 84% (Supplementary Table S1).
Treatment Utilization
Of the 865 (40%) patients who received one or more of 
the exposures of interest, the most common treatment uti-
lized was hydroxychloroquine plus azithromycin (n = 203, 
23%), followed by hydroxychloroquine alone (n = 179, 21%), 
azithromycin alone (n = 160, 18%), remdesivir alone (n = 57, 
7%), hydroxychloroquine plus azithromycin plus high-dose 
corticosteroids (n = 24, 3%), high-dose corticosteroids alone 
(n = 18, 2%), hydroxychloroquine plus tocilizumab (n = 18, 
2%), and hydroxychloroquine plus azithromycin plus tocili-
zumab (n = 18, 2%). Various other treatment combinations 
were reported less frequently, with a total of 49 different 
treatment patterns observed (Fig. 3).
Of note, tocilizumab was rarely given alone, whereas the 
other treatments examined had subsets of monotherapy 
exposure exceeding 1%. There were differences in patterns 
of treatment for ever-hospitalized versus never-hospitalized 
patients, with no receipt of more than two agents in combina-
tion for never-hospitalized patients (Supplementary Figs. S1 
and S2). Patients most frequently received remdesivir as part 
of a clinical trial (n = 86, 69%), whereas use of other agents 
was almost entirely outside the context of a specified trial.
Receipt of Therapies with Potential  
Anti–COVID-19 Effects
Medication utilization was examined using multivari-
able logistic regression (MLR) analysis to assess likelihood 
for receipt of treatment with (i) hydroxychloroquine plus 
azithromycin, (ii) remdesivir (with or without any other con-
comitant therapy), and (iii) any treatment of interest. Group 
assignments to the exposure of interest, positive controls, 
and negative controls are shown in Fig. 4 and Supplemen-
tary Table S2. There was no statistically significant inter-
action between race/ethnicity and hypertension or renal 
comorbidities. Goodness of fit is shown in Supplementary 
Table S3; all variance inflation factors (VIF) for all models 
were less than five. Across all treatment groups examined, 
baseline COVID-19 severity had the strongest association 
with treatment, with a stepwise increase from moderate to 
severe (Table 1).
In addition, the following characteristics were associated 
with receipt of hydroxychloroquine plus azithromycin treat-
ment: patients in the U.S. West were less likely to receive 
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Figure 1.  CONSORT diagram (top) and registry accrual (bottom) during the data collection period of March 17 to June 26, 2020. Red points repre-
sent included cases; blue points represent excluded cases. 1Hydroxychloroquine (HCQ), azithromycin, remdesivir, high-dose systemic corticosteroids, 
tocilizumab, or other COVID-19 treatments; 2Only excluded if patient has a baseline autoimmune condition; 3Only excluded if patient has baseline chronic 
obstructive pulmonary disease, asthma, or HIV; 4Only excluded if patient has baseline HIV.
Total completed surveys
(n = 2,956)
Excluded (n = 439)
• Duplicates or false positive (n = 16)
• Non–laboratory-confirmed COVID-19 (n = 150)
• Age < 18 (n = 5)
• In situ cancer (n = 35)
• Residence outside US (n = 233)
Excluded (n = 331)
• Missing or unknown exposure1 data (n = 202)
• Receiving HCQ2, azithromycin3, tocilizumab2,
  high-dose systemic corticosteroids, atazanavir4, or
  lopinavir/ritonavir4 at baseline (n = 107)
• Unknown comorbidities (n = 11)
• Unknown baseline COVID-19 severity (n = 7)
• May have died more than 30 days after COVID-19

















hydroxychloroquine plus azithromycin [adjusted odds ratio 
(aOR), 0.34; 95% confidence interval (CI): 0.17–0.69] as were 
patients with cardiovascular conditions (aOR, 0.68; 95% CI: 
0.48–0.98). Patients with renal conditions were more likely 
to receive hydroxychloroquine plus azithromycin (aOR, 1.56; 
95% CI: 1.09–2.23).
The following additional characteristics were associated 
with a decreased likelihood of receiving remdesivir: non-
Hispanic Black patients versus non-Hispanic white patients 
(aOR, 0.56; 95% CI: 0.31–1.00; Supplementary Table S4); renal 
comorbidities (aOR, 0.32; 95% CI: 0.16–0.61); and ECOG PS 
of 2+ (aOR, 0.47; 95% CI: 0.24–0.90). Patients residing in the 
U.S. West were more likely to receive remdesivir (aOR, 1.85; 
95% CI: 1.09–3.15). Increasing age was numerically associated 
with a decreased likelihood of remdesivir treatment, although 
this did not reach statistical significance (aOR, 0.87; 95% CI: 
0.74–1.03).
The following additional characteristics were associated with 
increased likelihood of receipt of any treatment: male sex (aOR, 
1.28; 95% CI: 1.04–1.56), obesity (aOR, 1.44; 95% CI: 1.16–1.80), 
presence of pulmonary comorbidities (aOR, 1.41; 95% CI: 1.10–
1.80), and presence of hypertension (aOR, 1.28; 95% CI: 1.02–
1.60). Patients with cardiovascular comorbidities were less likely 
to receive any treatment (aOR, 0.77; 95% CI: 0.61–0.98), as were 
patients with ECOG PS of 2+ (aOR, 0.72; 95% CI: 0.52–1.00), and 
those residing in the U.S. West (aOR, 0.63; 95% CI: 0.45–0.87).
Primary Outcome
At the time of this analysis, median follow-up for the 
included patients was 30 days (IQR, 10.5–42 days). Of the 357 
(16%) patients who were deceased at the time of data lock, 
329 (92%) died within 30 days, yielding a primary outcome 
rate of 15%. Goodness of fit is shown in Supplementary Table 
S3; all VIFs for all models were less than five.
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Figure 2.  Heat map of selected clinical factors stratified by treatment exposures. Coloration depicts the absolute departure from the average for that 
category; for example, patients with obesity were overrepresented in the tocilizumab exposure group by more than 16% of the average level of obesity 
in the total population (51% vs. 32%); patients with renal comorbidities were underrepresented in the remdesivir exposure group by 6% to 10% below 
the average level of renal comorbidities in the total population (9% vs. 18%). aPercentages add up to more than 100 because some patients had multiple 
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Propensity score matching (PSM) was undertaken to 
improve covariate balance and comparability between the 
comparator groups within the cohort as compared to the 
model with unmatched controls (Supplementary Table S5; 
Supplementary Fig. S3). As shown in Table 2, patients receiv-
ing hydroxychloroquine plus any other therapy had a statis-
tically significant increased risk of 30-day all-cause mortality 
compared with positive controls in matched and unmatched 
models (PSM aOR, 1.99; 95% CI: 1.29–3.08; unmatched aOR, 
1.93; 95% CI: 1.27–2.94). Hydroxychloroquine treatment 
alone was not associated with increased risk (PSM aOR, 1.03; 
95% CI: 0.62–1.73; unmatched aOR, 0.98; 95% CI: 0.59–1.62). 
Compared with negative controls, results are similar with an 
increased risk among those receiving hydroxychloroquine 
plus any other therapy (PSM aOR, 2.15; 95% CI: 1.51–3.06; 
unmatched aOR, 2.50; 95% CI: 1.74–3.59), with no increased 
risk for hydroxychloroquine alone. In addition, mortality 
associated with hydroxychloroquine exposure was modeled 
excluding severe cases. With this exclusion, there was an 
increased magnitude of the effect on the primary outcome 
for patients receiving hydroxychloroquine plus any other 
therapy versus positive controls (aOR, 2.58; 95% CI: 1.53–
4.33) and negative controls (aOR, 3.86; 95% CI: 2.50–5.98). 
When the analysis was restricted to patients with active 
cancer, the findings were similarly increased (Table 2). Addi-
tional statistical methods including logistic regression with 
elastic-net and horseshoe regularization were conducted 
to ensure robustness and yielded similar results (Supple-
mentary Tables S6 and S7). The Average Causal Mediation 
Effects (ACME) 95% CI showed that the mediation effect of 
baseline COVID-19 severity was not significantly different 
from zero and the proportion of the ACME in the total effect 
was quite small, that is, 4% (Supplementary Table S8).
Remdesivir
Remdesivir alone was associated with decreased 30-day all-
cause mortality in comparison with positive controls (aOR, 
0.41; 95% CI: 0.17–0.99) and was numerically associated with 
a decreased likelihood of mortality in comparison with nega-
tive controls, although this did not reach statistical signifi-
cance (aOR, 0.76; 95% CI: 0.31–1.85; Table 3).
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Figure 4.  Distribution of matched and unmatched cohorts stratified by exposure of interest (EOI). Negative controls are patients who did not have 
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 table 1.   factors associated with receipt of COVID-19 therapy 
Characteristics
Hydroxychloroquine & 
azithromycin, aOR (95% CI) Remdesivir, aOR (95% CI)
Any treatment, 
aOR (95% CI)
Number exposed  N = 203 a  N = 124 b  N = 865
Age c 0.97 (0.85–1.11) 0.87 (0.74–1.03) 0.96 (1.05–1.14)
Sex
 Male vs. female 1.30 (0.95–1.77) 1.24 (0.84–1.85) 1.28 (1.04–1.56)
Race/ethnicity
 Hispanic vs. non-Hispanic white 0.73 (0.44–1.20) 1.22 (0.71–2.11) 0.96 (0.70–1.31)
 Non-Hispanic Black vs. non-Hispanic white 0.82 (0.57–1.19) 0.56 (0.31–1.00) 1.13 (0.87–1.46)
 Other vs. Non-Hispanic white 0.65 (0.36–1.16) 0.56 (0.26–1.22) 1.01 (0.71–1.45)
Region of patient residence
 U.S. Midwest  vs. U.S. Northeast 0.90 (0.63–1.31) 0.79 (0.47–1.33) 0.89 (0.70–1.14)
 U.S. South  vs. U.S. Northeast 1.34 (0.87–2.07) 1.03 (0.56–1.90) 0.84 (0.61–1.15)
 U.S. West  vs. U.S. Northeast 0.34 (0.17–0.69) 1.85 (1.09–3.15) 0.63 (0.45–0.87)
Smoking status
 Current or former smoker  vs. never-smoker 1.06 (0.77–1.47) 0.90 (0.58–1.38) 0.99 (0.80–1.24)
Comorbidities
 Obese vs. not obese 1.07 (0.77–1.49) 1.32 (0.87–2.00) 1.44 (1.16–1.80)
 Diabetes mellitus present vs. absent 1.16 (0.84–1.61) 0.84 (0.55–1.30) 0.99 (0.79–1.24)
 Pulmonary comorbidities present vs. absent 1.09 (0.76–1.56) 1.53 (0.98–2.40) 1.41 (1.10–1.80)
 Cardiovascular comorbidities present vs. absent 0.68 (0.48–0.98) 1.15 (0.74–1.79) 0.77 (0.61–0.98)
 Renal comorbidities present vs. absent 1.56 (1.09–2.23) 0.32 (0.16–0.61) 1.02 (0.79–1.33)
 Hypertension present vs. absent 1.11 (0.78–1.58) 1.31 (0.84–2.04) 1.28 (1.02–1.60)
ECOG performance status
 1 vs. 0 1.07 (0.71–1.63) 0.72 (0.43–1.21) 1.25 (0.95–1.64)
 2+ vs. 0 0.77 (0.46–1.28) 0.47 (0.24–0.90) 0.72 (0.52–1.00)
 Unknown vs. 0 1.10 (0.71–1.71) 1.00 (0.59–1.69) 1.10 (0.83–1.47)
Cancer status
 Active, progressing vs. remission/NED 0.94 (0.57–1.55) 1.03 (0.55–1.93) 0.99 (0.71–1.39)
 Active, stable or responding vs. remission/NED 0.90 (0.62–1.32) 1.18 (0.74–1.88) 1.01 (0.79–1.29)
 Unknown vs. remission/NED 0.81 (0.48–1.38) 0.72 (0.36–1.45) 0.98 (0.69–1.39)
Baseline COVID-19 severity
 Moderate vs. mild 5.68 (3.66–8.82) 9.88 (5.26–18.6) 7.53 (5.96–9.53)
 Severe vs. mild 6.80 (4.07–11.4) 21.2 (10.7–42.0) 11.9 (8.60–16.5)
a This includes patients who received hydroxychloroquine and azithromycin without any other COVID-19 treatments. 
b This includes patients who received remdesivir whether or not they received other COVID-19 treatments. 
c Risk per decade. 
 High-Dose Corticosteroids 
 High-dose corticosteroids alone were numerically but 
not significantly associated with increased 30-day all-
cause mortality versus negative controls (aOR, 2.8; 95% 
CI: 0.77–10.15). High-dose corticosteroids plus any other 
therapy was associated with increased mortality in com-
parison with positive and negative controls, respectively 
(aOR, 2.04; 95% CI: 1.19–3.49 and 3.16; 95% CI: 1.80–5.54;
 Table 3 ). 
 Tocilizumab 
 Because of insuffi cient numbers of independent exposures, 
tocilizumab exposure was reported for descriptive purposes 
only and not analyzed further. 
 Clinical and Demographic Factors 
 Across all of the examined treatment groups, explora-
tory analysis of potential factors associated with 30-day 
all-cause mortality showed increases in patients with 
increased age, increased baseline COVID-19 severity, 
patients with active cancer (progressing or stable/respond-
ing), and patients with an ECOG PS of 2+, similar to 
our initial findings. Decreased mortality was associated 
with residence in the U.S. Midwest region (Supplementary 
Table S9). Individual comorbidities were not statistically 
significant in these analyses, nor were sex, race/ethnicity, 
smoking status, and receipt of anticoagulation; however, 
these factors were not independently tested for formal 
significance. 
CCC19 Treatment Utilization Study RESEARCH ARTICLE
 OCTOBER  2020 CANCER DISCOVERY | 1521 
 discussion 
 In this largest currently available cancer-specifi c observa-
tional study of treatments purported to improve COVID-19 
outcomes, use of therapies was frequent and highly variant, 
likely due to patient, prescriber, and access factors. We did not 
fi nd evidence of benefi t, with the possible exception of rem-
desivir as compared with positive controls. Conversely, the 
receipt of hydroxychloroquine with other medications (most 
commonly azithromycin) remained associated with increased 
30-day all-cause mortality, after extensive adjustment. The 
encouraging fi ndings for corticosteroids in the prospective 
UK RECOVERY trial were not replicated in this cohort of 
patients with cancer. Although this study was not designed to 
independently examine other clinical factors associated with 
30-day all-cause mortality, most of the additional covariates 
were consistent with our initial observations, with the nota-
ble exception of sex, which was numerically but no longer 
statistically associated with mortality. 
 With the limited availability of RCT data to support clini-
cal decision-making in oncology, observational studies are 
necessary to provide a timely understanding of real-world 
practice. Observational studies have a role in supporting 
understanding of drug utilization and real-world outcomes 
while awaiting prospective trials to establish the causality of 
these associations, complementing each other in a rapid cycle 
of evidence generation to meet the needs of the pandemic 
( 4 ). Although observational studies have emerged rapidly to 
identify potential treatments for COVID-19, they have pro-
duced confl icting evidence and raised concerns over accuracy 
of reported associations ( 5, 6 ). Robust adjustment for poten-
tial confounding is necessary in such studies, especially con-
founding by disease severity, as sicker patients are more likely 
to receive the treatments of interest. Likewise, the results of 
observational studies may be confounded by lack of access to 
therapeutic agents due to variable health system limitations, as 
well as sociodemographic barriers and regional differences ( 7 ). 
 Functioning at record pace, the scientifi c community is 
evaluating new drugs, developing vaccine candidates, and 
studying drugs for repurposing because there is an impera-
tive to meet current global health needs in the COVID-19 
pandemic. The array of new and existing drugs being evalu-
ated for therapeutic use in SARS-CoV-2 infection includes 
hydroxy chloroquine, azithromycin, antivirals, immunomodu-
latory mAbs, interleukin inhibitors, cytokine blockers, his-
tamine antagonists, corticosteroids, kinase inhibitors, and 
protease antagonists, among other drugs, some of which 
were previously studied for other emerging respiratory 
viruses ( 8 ). Ongoing multiarm RCTs including the WHO 
Solidarity trial (NCT04321616) and the UK RECOVERY trial 
 table 2.   Evaluation of 30-day all-cause mortality associated with hydroxychloroquine exposure, as compared with 
positive (treated) and negative (untreated) controls using different methodological approaches 
Treatment exposure




Without severe cases, 
aOR (95% CI) a 
HCQ, active cancer only, 
aOR (95% CI) a 
HCQ alone vs. positive control 1.03 (0.62–1.73) 0.98 (0.59–1.62) 1.01 (0.55–1.85) 1.05 (0.47–2.35)
HCQ + any other exposure vs. 
positive control
1.99 (1.29–3.08) 1.93 (1.27–2.94) 2.58 (1.53–4.33) 2.44 (1.27–4.69)
HCQ alone vs. negative control 1.11 (0.71–1.74) 1.27 (0.80–1.99) 1.52 (0.90–2.57) 1.25 (0.61–2.57)
HCQ + any other exposure vs. 
negative control
2.15 (1.51–3.06) 2.50 (1.74–3.59) 3.86 (2.50–5.98) 2.91 (1.69–4.99)
Positive control vs. negative 
control
1.08 (0.70–1.65) 1.30 (0.87–1.94) 1.50 (0.92–2.45) 1.19 (0.64–2.24)
a Unmatched controls. 
 table 3.   Evaluation of 30-day all-cause mortality associated with additional exposures of interest, as compared with 
positive (treated) and negative (untreated) controls 
Treatment exposure Remdesivir, aOR (95% CI) a 
High-dose sytemic corticosteroids, 
aOR (95% CI) a 
EOI vs. positive control 0.41 (0.17–0.99) 1.81 (0.50–6.56)
EOI + any other exposure vs. positive control 0.57 (0.28–1.16) 2.04 (1.19–3.49)
EOI vs. negative control 0.76 (0.31–1.85) 2.80 (0.77–10.2) a 
EOI + any other exposure vs. negative control 1.06 (0.51–2.18) 3.16 (1.80–5.54)
Positive control vs. negative control 1.85 (1.36–2.51) 1.55 (1.14–2.11)
 Abbreviation: EOI, exposure of interest. 
 a Precision of estimation for this category is poor. 
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(NCT04381936) are prospectively evaluating these therapeu-
tic strategies nationally and globally. ClinicalTrials.gov has 
more than 1,000 registered interventional trials for COVID-19 
as of July 2020, the majority of which are actively recruiting.
Within the context of biological plausibility (9–14), our 
study provides an overview of treatment utilization and thera-
peutic outcomes among patients with cancer and COVID-
19 across various potential candidate drugs of interest. In 
observational studies such as this, isolation of the treatment 
effect is complicated due to nonrandomized, non–strictly 
controlled conditions for treatment; however, this is a useful 
indicator of what occurs in real-world clinical settings. As 
shown in Fig. 3, the utilization of medications in this cohort 
is not straightforward and indicates the use of multiple drug 
combinations and therapeutic strategies, including intense 
multiagent use in some cases. Making matters more complex, 
the cancer population in this cohort is heterogeneous, with 
a variety of histologic subtypes and differing cancer statuses. 
This heterogeneity is reflective of real-world practice. Notably, 
43% of patients with progressing cancer who were not actively 
receiving cancer treatment still received COVID-19 treatment.
In the secondary hypothesis-generating analysis, medica-
tion utilization in the observed population indicates con-
cordance with clinical evaluation of patient comorbidities. 
Patients with increased baseline COVID-19 severity were sig-
nificantly more likely to receive any treatment. The differen-
tial use of anticoagulants in the treated population further 
indicates the role that disease severity may have had in treat-
ment use. Males, obese patients, and those with hypertension 
were more likely to receive any anti–COVID-19 therapy, likely 
reflecting clinical decision-making within the context of the 
emerging literature on COVID-19 vulnerabilities (15). Use 
of hydroxychloroquine plus azithromycin was less likely in 
patients with cardiovascular conditions, perhaps driven by 
awareness of the synergistic potential risk of QT prolonga-
tion and torsades de pointes (16, 17). Use of remdesivir 
was less likely in patients with renal impairment, a specific 
exclusion criteria in clinical trials and compassionate-use 
programs (18). Aside from remdesivir, few of the other thera-
pies were administered as part of a formal clinical study, and 
no patients in this cohort received high-dose corticosteroids 
on trial.
The results also indicated a decreased likelihood to receive 
treatment with remdesivir for Black patients, adding to a 
growing literature of concern around disparities of outcomes 
in COVID-19 (19–21). Although there was no apparent inter-
action between race/ethnicity and hypertension or renal 
comorbidities in our population, the interaction analysis 
was relatively underpowered and does not exclude other, 
untested, interactions. Nevertheless, historically underrep-
resented populations are prone to disparities in health out-
comes throughout the U.S. health care system, both within 
and outside the context of clinical trials (22). As the CCC19 
cohort continues to grow, we will continue to carefully exam-
ine possible racial and ethnic inequities in treatment expo-
sures and in outcomes.
Similar to our first analysis and other smaller series, the 
CCC19 updated cohort confirms high all-cause mortality 
among patients with cancer infected by the SARS-CoV-2 virus 
(n = 357, 16%), remaining significantly higher than the 2% to 
7% reported in the general population (23–30). The findings 
from the PSM and unmatched models in this study as well as 
the model excluding severe cases are consistent with available 
published observational studies alongside clinical trial data 
suggesting the lack of benefit for use of hydroxychloroquine 
(31). In the RECOVERY trial of hospitalized patients with 
COVID-19, no benefit was found for hydroxychloroquine, 
and the arm was closed early (per press release at https://
www.recoverytrial.net/results/hydroxychloroquine-results). 
In the same trial, dexamethasone was associated with reduced 
mortality in ventilated patients and patients receiving oxy-
gen (3). Although these findings were not replicated in this 
cohort of patients with cancer, where corticosteroids with 
other COVID-19 treatments were associated with increased 
mortality, the limited number of patients exposed to corti-
costeroid monotherapy within our cohort (n = 18) indicates 
the need for additional study to improve the precision of the 
estimate. Nevertheless, given that patients with cancer were 
not explicitly defined in the RECOVERY trial, caution needs 
to be taken when extrapolating the results to a population of 
patients with cancer.
Although the association between remdesivir versus nega-
tive controls and reduction in 30-day all-cause mortality was 
not statistically significant, it is consistent with literature 
suggesting that the drug may lessen disease severity or reduce 
the duration of infection, similar to currently approved anti-
virals for other conditions. Promising results for remdesivir 
are shown versus positive controls and were reported in 
small series, including in a cohort of patients hospitalized 
for severe COVID-19, with clinical improvement observed in 
68% of 53 patients (32, 33). More recently, the likely pivotal 
RCT of remdesivir was published, with a significantly faster 
time to improvement versus placebo (P < 0.001) as well as 
a HR for death at 14 days of 0.70 (95% CI: 0.47–1.04; ref. 
34). Of note, this HR for mortality is numerically similar to 
our observed aOR for 30-day mortality in remdesivir versus 
negative control (0.76; 95% CI: 0.31–1.85. The definition of 
an ideal comparator group in our real-world setting is com-
plicated, as the positive controls included patients exposed to 
hydroxychloroquine.
After IL6 was shown to be a potential key driver in the 
cytokine storm upon SARS-CoV-2 infection, tocilizumab has 
been used in multiple small series, with a recent retrospec-
tive study showing a reduction in risk of invasive mechanical 
ventilation or death in 179 treated patients among 1,351 
with severe COVID-19 pneumonia (14). Because tocilizumab 
was not frequently used and when used was almost never 
given alone or without hydroxychloroquine (Fig. 3), we were 
unable to isolate any effect of tocilizumab. Ongoing pro-
spective randomized trials in noncancer populations (e.g., 
NCT04356937, NCT04372186) and nonrandomized trials 
in cancer populations (NCT04370834) may help to further 
clarify the role of this agent.
This study is limited by the lack of randomization and 
potential for selection bias, including lack of access to clini-
cal trials or expensive therapies. Confounding by severity 
is a concern in this population, as patients with increased 
baseline severity were more likely to be treated with one or 
more therapies. Collider bias and channeling associated with 
treatment may also affect assessment of the associations 
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(35, 36). Although adjustments and varying methodologic 
techniques were applied, residual confounding may affect 
the results, and causality cannot be established. For exam-
ple, socio demographic factors which may adversely affect 
outcomes are not yet captured with fidelity in the CCC19 
registry. The study is not population-based, and generaliz-
ability to other populations may be limited. Aside from 
hydroxychloroquine, PSM was unable to be conducted due to 
a relatively small number of exposures and events. Although 
active cancer treatments are collected in analyzable form, they 
are not currently sufficiently granular to determine whether 
certain specific treatments are associated with treatment 
exposure decisions and/or outcomes; this is a focus of future 
work. Another limitation is the lack of temporal associations 
due to institutional review board (IRB) restrictions on timing 
data collection as well as the feasibility of collecting granular 
data at scale, including calculation of time to event data and 
adjustment for COVID-19 progression, as disease severity is 
only able to be estimated as baseline severity. Finally, unseen 
trends such as temporal evolution of treatment strategies as 
knowledge of COVID-19 has evolved may have affected the 
results; these trends are also intrinsically tied into institu-
tional treatment protocols and the geographical distribution 
of the infection, and future studies can evaluate this phenom-
enon with expanded longitudinal data capture.
conclusion
Treatments utilized in patients with COVID-19 and can-
cer included hydroxychloroquine, azithromycin, remdesivir, 
high-dose corticosteroids, tocilizumab, and other therapies 
alone and in combination. Treatment patterns appear to be 
complex, especially because of the evolving use of experimen-
tal therapies and knowledge around the multisystem effects 
of COVID-19. With the exception of remdesivir, the majority 
of treatments received by our study population were admin-
istered outside the context of clinical trials. Isolation of the 
treatment effect is therefore challenging. This study included 
multiple methods to emphasize replicability of estimate valid-
ity and evaluate the primary concerns of selection bias and 
confounding by severity. Our findings add to the emerging 
understanding of nonbeneficial impact of hydroxychloro-
quine and suggest a potentially beneficial impact of remdesi-
vir, while also highlighting the racial disparities in enrollment 
of clinical trials of potentially beneficial experimental thera-
pies. We encourage the evaluation of these treatments in 
prospective RCTs, along with systematic efforts to assess and 
address disparities and promote health equity in current stud-
ies evaluating potentially effective anti–COVID-19 therapies.
Methods
Data Sources and Study Population
Data were collected through the CCC19 registry, an international 
collaboration of cancer centers (Supplementary Appendix) and anon-
ymous healthcare providers providing data through a comprehensive 
REDCap survey for patients with COVID-19 and cancer. Detailed 
methodology has been previously described (2, 37, 38). Only deiden-
tified data are collected, and the study was considered exempt from 
IRB review (VUMC IRB#200467) and was approved by local institu-
tional IRBs at participating sites per institutional policy, according to 
principles of the Declaration of Helsinki. This study is registered on 
ClinicalTrials.gov (NCT04354701).
Eligible cases included U.S. adult patients with current or his-
tory of invasive cancer and laboratory-confirmed SARS-CoV-2 
infection with baseline forms (demographics, initial course of 
COVID-19 illness, and cancer details) completed between March 
17 and June 26, 2020. The following exclusion criteria were then 
applied (CONSORT diagram; Fig.  1): (i) unknown or missing 
treatment exposures of interest; (ii) autoimmune conditions and 
taking hydroxychloroquine or tocilizumab at baseline; (iii) chronic 
obstructive pulmonary disease (COPD), asthma, or HIV and taking 
azithromycin at baseline; (iv) high-dose corticosteroids at baseline 
unless manual review confirmed that the high-dose corticosteroids 
were being given as a treatment for acute viral illness; (v) HIV and 
taking lopinavir/ritonavir or atazanivir at baseline; (vi) unknown 
baseline comorbidities; (vii) unknown baseline severity of COVID-
19; and (viii) deceased patients with insufficient information to 
determine whether they died within the 30-day window.
Exposure and Outcome Measurement
Treatment exposures were recorded as binary for the following 
drugs: (i) hydroxychloroquine; (ii) azithromycin; (iii) high-dose 
corticosteroids (defined as receipt of ≥ 20 mg/day of prednisone 
dose equivalents); (iv) remdesivir; (v) tocilizumab; and (vi) other, 
which included chloroquine, lopinavir/ritonavir, atazanavir, barici-
tinib, plasma from convalescent individuals, IL inhibitors other 
than tocilizumab, TNFα inhibitors, and any other treatment given 
within the context of a clinical trial of COVID-19 treatment. 
Drug exposures were recorded by respondents in three locations 
within the REDCap survey (Supplementary Table S10), where they 
were asked to choose from a structured multiselect option for: 
(i) “Concomitant medications being taken at time of presenta-
tion with COVID-19” (concomitant_meds); (ii) “COVID-19 treat-
ment, including preexisting drugs that were continued during the 
COVID-19 diagnosis” (covid_19_treatment); and (iii) “Additional 
COVID-19 treatment” (covid_19_treatment_fu). For the COVID-
19–specific variables, they were additionally asked whether any of 
the selected drugs were given within the context of a clinical trial 
(covid_19_trial_tx and covid_19_trial_tx_fu). Additional free text 
entries allowed for optional detailed explanations, for example, 
drug dosing and indication. With the exception of high-dose sys-
temic corticosteroids, which were manually reviewed for free text 
indicating short-course administrations in the context of viral ill-
ness, all medications selected on the patient demographics form 
were defined to be taken at baseline. Intermittent steroids being 
given for cancer treatment were converted into daily prednisone 
dose equivalents, for example, dexamethasone 20 mg weekly for 3 
out of 4 weeks for multiple myeloma was calculated as 14.3 mg/day 
of prednisone dose equivalents.
Each exposure of interest was examined in isolation (i.e., only that 
drug was prescribed to a particular patient) and in combination with 
any of the other treatment exposures defined above. These exposed 
groups were then compared against two control populations: (i) 
positive controls, defined as patients receiving any of the defined 
treatments in the absence of the drug of interest; and (ii) negative 
controls defined as patients receiving none of the defined treatments 
(i.e., an unexposed, untreated control). For each drug exposure, 
factors associated with medication utilization were evaluated. The 
primary outcome was the impact of each drug of interest on 30-day 
all-cause mortality.
Statistical Analysis
Multivariable Logistic Regression (MLR) Model. Evaluation of 
medication utilization was examined using an MLR model with 
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baseline covariates adjustment to assess likelihood for receipt of 
treatment. The primary evaluation of 30-day all-cause mortality 
within the context of hydroxychloroquine exposure and the second-
ary evaluations of remdesivir and high-dose systemic corticosteroids 
were also conducted using MLR with baseline covariates adjust-
ment. The aOR for treatment exposure and mortality associa-
tion were modeled using the following baseline variables: age, sex, 
self-reported race, and ethnicity (as available in electronic medical 
records), region of patient residence, smoking status, obesity (body 
mass index greater than or equal to 30 mg/m2), hypertension, dia-
betes mellitus, cardiovascular, pulmonary, and renal comorbidities, 
ECOG PS, cancer status, and baseline severity of COVID-19. The 
models for mortality association were additionally adjusted for 
exposure to anticoagulants or antiplatelet agents (ever/never), and 
the treatment exposures of interest. Tests of interaction were per-
formed for (i) race/ethnicity and hypertension and (ii) race/ethnicity 
and renal comorbidities.
Cardiovascular comorbidities were defined as any of the follow-
ing: coronary artery disease, congestive heart failure [including heart 
failure with preserved ejection fraction (HFpEF) and with reduced 
ejection fraction (HFrEF)], atrial fibrillation, cardiac arrhythmias not 
otherwise specified (NOS), peripheral vascular disease, or history of 
cerebrovascular accident. Pulmonary comorbidities were defined as 
any of the following: COPD, asthma, previous history of radiation 
pneumonitis, immune checkpoint inhibitor-related pneumonitis, or 
pulmonary disease NOS. Renal comorbidities were defined as any 
of the following: chronic kidney disease, end-stage renal disease 
with or without dialysis, and renal disease NOS. Baseline severity of 
COVID-19 was defined by the local investigator as mild (no hospitali-
zation indicated); moderate (hospitalization indicated, whether or 
not it occurred); and severe (intensive care unit admission indicated, 
whether or not it occurred). With the exception of ECOG PS and 
cancer status, unknown values were redefined as missing. Before con-
ducting the regression analyses, we performed multiple imputation 
for the missing values using additive regression, bootstrapping, and 
predictive mean matching.
Precision Analysis.  The precision analysis was focused on the 
evaluation of 30-day all-cause mortality within the context of hydroxy-
chloroquine exposure. It was completed using 5,000 computer simu-
lations based on a generalized linear model (GLM). With the study 
sample size of 2,186 (hydroxychloroquine alone = 179, hydroxy-
chloroquine + any other exposure = 359, negative controls = 1,321, 
and positive controls = 327), the largest half-width of the 95% con-
fidence intervals of the precision ratio, that is, standard error (SE) 
of the estimated OR divided by estimated OR, among all-pairwise 
comparisons is less than 3% without multiple comparison adjust-
ment (Supplementary Data). Therefore, it is reassured that our study 
has excellent precision of the reported results.
PSM Method. Because of sufficient numbers of exposures and 
events based on degrees of freedom, the evaluation of hydroxychlo-
roquine utilized a PSM regression model assessing the treatment 
exposure and primary outcome for robustness and validation; other 
drug exposures were too infrequent to utilize the PSM method. 
Because of the multiple control and exposure groups, we consid-
ered “pseudo” propensity score matching to balance the covariate 
distributions in the treatment groups. Instead of directly balancing 
the covariate distributions in the four treatment groups, “pseudo” 
propensity score matching balanced the covariate distribution in 
two “pseudo” groups: the control unit, which consists of the nega-
tive and positive control groups, and the treated unit, which consists 
of hydroxychloroquine alone and with other drugs. Other pairwise 
matchings were limited by the overall sample size. For the matching, 
we adopted the nearest-neighbor method with a 1:2 ratio (treated 
units: control units) and 0.3 SD of the distance measure within 
which to draw the control units, based on the optimal balance 
between loss of events and the maximum mean difference between 
the four groups (Supplementary Fig. S4). The parameters in match-
ing kept as many events as possible, and according to the χ2 test 
results, improved the balance of the covariate distributions in the 
four groups. After 5-run analyses (each run: multiple imputation 
+ matching + logistic regression analysis), the average results were 
reported.
Sensitivity Analyses. We conducted several sensitivity analyses to 
explore the robustness of the findings for the primary hypothesis of 
association of hydroxychloroquine exposures with 30-day all-cause 
mortality. First, we excluded patients with severe baseline COVID-19, 
as the disease course may be too advanced in these patients for 
any disease-modifying therapeutic activity. Second, we limited the 
analysis to patients with active cancer only, to evaluate the degree to 
which the findings might be specific to this subgroup. Third, we 
performed elastic-net and horseshoe regression analyses to explore 
whether these advanced statistical techniques provided additional 
insight beyond ordinary logistic regression. Fourth, we conducted 
a mediation analysis to determine the indirect effect of baseline 
COVID-19 severity.
Descriptive Statistics and Model Evaluation. We used descriptive 
statistics to display the baseline demographic information of the 
participants included in our analyses, including UpSet plots for 
visualizations of intersecting data (39). Goodness of fit was assessed 
by Harrell C-statistic (40). VIFs were computed for every covariate in 
each adjusted model. Statistical significance was preset as α = 0.05. 
All data analyses were performed using base R 4.0.0 (R Foundation) 
and the R packages rms 6.0-0, MatchIt 3.0.2, Hmisc 4.4-0, glmnet 
3.0-2, mediation 4.5.0, horseshoe 0.2.0, pROC 1.16.2, and UpSetR 
1.4.0 (41–49).
Data and Code Sharing
The dataset analyzed for the primary and secondary hypotheses 
will be made immediately available upon request; requests should 
be sent to contact@ccc19.org. All aggregate deidentified patient data 
with site identifiers removed and geographical region of patient resi-
dence masked to a level no smaller than U.S. Census Divisions will be 
made publicly available for any purpose through the CCC19 website 
(https://www.ccc19.org) beginning 6 months and ending 72 months 
after publication of this article. These data will be displayed with an 
interactive graphical tool, allowing for visual analytics of the data. 
Individual deidentified patient data with site identifiers removed and 
geographic region of patient residence masked to a level no smaller 
than U.S. Census Divisions will be made available to researchers who 
provide a methodologically sound proposal, and whose proposed 
use of the data has been approved by an independent review commit-
tee identified for this purpose. External proposals can be submitted 
beginning 6 months and up to 72 months after publication of this 
article; the CCC19 is open to additional collaborators as well. All pro-
posals should be directed to contact@ccc19.org; to gain access, data 
requestors will need to sign a data access agreement.
An abbreviated version of the data dictionary and pseudo-code to 
generate the derived variables used in the analysis are in Supplemen-
tary Tables S10 and S11. The full data dictionary and code used to 
create the derived variables and propensity score matching method 
are available upon request.
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